KRAS G12C + PD-L1 underexpression
|
NSCLC
|
KRAS G12C + PD-L1 underexpression
|
NSCLC
|
sotorasib Sensitive: C3 – Early Trials
|
sotorasib Sensitive: C3 – Early Trials
|
KRAS G12C + PD-L1 underexpression
|
NSCLC
|
KRAS G12C + PD-L1 underexpression
|
NSCLC
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|